TABLE 2.

Variables associated with S. aureus-related mortality in 294 patients with MSSA-B (cohort study)

CharacteristicUnivariate analysisMultivariate analysisaMultivariate analysisb
OR (95% CI)P valueAdjusted OR (95% CI)P valueAdjusted OR (95% CI)P value
Old age (≥65 yr)1.4 (0.8-2.5)0.29
Male gender1.0 (0.6-1.8)0.98
Community-acquired infection1.2 (0.7-2.2)0.52
McCabe classification (ultimately fatal or rapidly fatal)7.3 (2.8-19.0)<0.0012.7 (0.9-7.7)0.062.7 (0.9-7.7)0.06
Underlying diseases
    Solid tumor6.8 (3.6-13.1)<0.0014.7 (2.2-9.9)<0.0014.8 (2.2-10.3)<0.001
    Hematologic malignancy0.4 (0.2-1.0)0.06
    Liver cirrhosis4.5 (2.4-8.6)<0.0013.4 (1.6-7.3)0.0023.4 (1.6-7.4)0.002
    End stage renal disease0.4 (0.1-1.2)0.09
    Cardiovascular disease0.8 (0.3-2.5)0.75
Primary sites of infection
    Unknown3.0 (1.7-5.4)0.001
    Catheter-related infection0.1 (0.0-0.4)0.002
    Pneumonia2.6 (1.1-6.0)0.032.7 (0.9-7.3)0.0462.7 (0.9-7.3)0.06
    Soft tissue infection0.6 (0.2-1.5)0.30
    Surgical wound infection0.8 (0.2-3.9)0.81
Eradicated foci of infection0.2 (0.1-0.4)<0.0010.3 (0.1-0.7)0.0060.3 (0.1-0.7)0.006
Infection acquired in intensive care unit1.6 (0.6-4.4)0.34
Inappropriate empirical treatment1.0 (0.4-2.3)0.98
Vancomycin treatment2.8 (1.2-6.4)0.023.4 (1.2-9.3)0.023.3 (1.2-9.5)0.02
  • a Adjusted for the variables associated with S. aureus-related mortality.

  • b Adjusted for the variables associated with S. aureus-related mortality and the propensity score of each patient's likelihood of being treated with vancomycin.